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El781 6 Do Patienta With Previous CABG Hsve WoraeOutcomas With Thrombolytic Therspy?
T.D. Henry, G.R. McKendall, M.J. Schweiger, E.M. Antman for the TIMI 9B
Investigators. Hennepin County Medical Centec Minneapolis, MN, USA,
Brigham and Women’s Hospital, Boston, MA, USA
Limited data are available on the outcome of patients (pts) with previous
CABG treated with thrombcdyfic therapy (U), since these pts have been
excluded from most randomized cllnicel trials. TIMI 9Bwas a randomizedtrial
comparing hirudin vs. heparin in conjunction with U in 2993 pts with acute
myocsrdial infarction (Ml). We reviewad the characteristics and outcomes
of 107 pts (4%) with previous CABG. Compared to pts without previous
CABG, they were older, more likely to have hypertension, hypeflipidemia,
peripheral and cerebral vaecular disease, but less often current smokers.
They also were more likely to have had previous Ml (65% vs. 14%+),angina
(67% va. 29%*), and PTCA (31% vs. 5%*). At time of enrollment, a greater
proportion were receiving aspirin (73% vs. 22%*), beta-blockers (37% vs.
13%*), ACE inhibitore (20% vs. 7%*), and nitrates (32% vs. 15%*). There
was no difference between groups in the number of pts receiving cardiac
catheterization, PTCA, or CABG. By 30 days, pts with previous CABG had
significantly higher rates of eardiogenic shock and recurrent Ml and tended
to have higher mortality. However, in a multivanate analysis previous CABG
was not an independent riak factor for death or Ml.
n Shock Ml (30day) Death (30day)
PMVIOUSCABG 107 11%” 16.2”At s.5%. ... —..——
No CABG 2SS6 4% 10.3% 5.S%
“p< 0.001, *p< 0.05
Cone/uaion:Patientswith previous CABGtreated with TTcOnstitute a high
riak group with a highar rate of adverse outcomes. While clinical outcomes
are worse, previous CABG is not an independent risk factor for death or Ml.
While these pts had a higher incidence of adverse risk factors, they were
also more Ilkelyto be on cardioprotective medications (aspirin, beta-blockers,
ACE inhibitors) prior to treatment.
n782 Stents: Does High Pressure DeploymentIncrease Restenosk?
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~] ~~;;~~;;~raSSUreStent E~PSnSiOnln~U~a MOra
T. Akiyama, C. Di Mario, B. Reimere, M. Ferraro, 1.Moussa, S. Blengino,
A. Colombe. Columbus Clinic, Milan, Italy
High-pressure stent dilatation haa virtually eliminated the risk of subacute
stent thrombosis but it can increaae wall damage and has been associated
with a higher risk of late reatenoais in recent reperk.. To tast this hypothesis,
all the 1181 lesions successfully treated with stent implantation receiving a
final ultrasound examination, were divided based on the maximal inflation
preasure of the largest balloon (S 16 ATMand >16 ATM). The’’low’’-pressure
group included 692 leaions (58.6%) and the high-pressure group 489 lesions
(41.4%). The Table below shows the percent diameter stenosis (DS) and
restenosis rate (=-507. DS) in the two groups, distinguishing in the high-
preesure group the subsets with optimal or suboptimal stent expansion (in-
etent minimal cresa-aectionai area ?60% of the nominal balloon area):
s 16 ATM >16 ATM Stent CSA
Suboptimal Optimal
BalloonDiameter (mm) 3,61 + 0.5e 3.73 * 0.39 3.46* 0.42 #
Max. Pressure (ATM) 13.7+ 2,3 18,S+ 1.5 18.5+ 1.2 t
Angioin-stentMLD (mm) 3.16+ 0.60 2.96 + 0.50 3.11 +0.47 *
FinalAngio‘A stenoais –2.9+ 10,5 1,4 * 14.7 -1,3+ 12.4 *
ICUS in-atentMLD (mm) 2.9 + 0.6 2.4 + 0.3 2.9+ 0,4 #
ICUS in-etantCSA (MM2) 8.04 + 2.95 5.71 * 1.33 7.60 + 1.88 #
F-Up Angio% OS 26.4 + 26.9 41.6 + 36.9 28.7 * 26.9 ~
F-Up Reetenosis(250°A DS) 19.5% 45.3% 21.1% $
incidence of restenosis was observed only when the final stent dilatation was
suboptimal despite high-pressure inflation.
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~] DoesthaLfseofAggre~siva StsntDi,aWtion Lead to
Mora Lste Loss snd Rastenosis?
S.L. Goldberg, A. Colombo, C. DiMario, P. Hall, Y. Almagor. /-farbor-UCfd
Madical CenteCTorrance,CA, USA, Centro Cuore Columbus, Milan, Italy
Stent expansion with high-pressure inflations has recently become etendard.
Does aggressivsstent dilatation encourage more intimal proliferation, leading
to increaaed late loss and restanosis, or does the achievement of a larger
lumen lead to less restenosis?
Angiographic and clinical resuits were compared in 726 atented vessels
divided into 3 consecutive groups: A: Traditional techniques, B: Oversized
balloons and C: High preasure inflations. Routine angiographic follow-up wee
performed in 80% at 4 to 8 months.
GroupA Group B GroupC P
N 233 17s 317
Balloon/artery 1.15 + 0.16 1.26* 0.20 1.16* 0.18 <0.001
Max Atm 9.0 * 1.9 12.4+ 3.7 14,7& 6.5 <0.001
Ref Ium (mm) 3.2 & 0.5 3.2 + 0.6 3.1 l 0.4 na
Length(mm) 10.6 + 7.5 10.O* 6.5 13.1 * 8.6 <0.001
MLD-pre (mm) 0.s + 0.5 0.9 * 0.5 0.8 + 0.5 na
FinalMLD (mm) 2.9 + 0.5 3.3 i 0.6 3.1 * 0.5
FU MLD (mm)
c 0.001
1.9 i 0.9 2.4 & 0.8 2.1 * 0.9 <0.001
Acute gain (mm) 2.1 + 0.7 2.5 + 0.9 2.3 A0,6 <0.001
Lete loss(mm) 1,0* 0.9 1.0 k 0.8 1.1 +0.8 ns
Complications 11% 13% 5“/4 <0,01
Angiorestenosis 32% 15Y0 24% <0,01
Clin restenoaie 26”A 18”A 20% <0,01
Conclusions: Baseline dimension were similar for the 3 groups exeept
for longer lesions in group 3. Aggressive stent expansion did not increase
late loss, but was associated with a lower rate of restenoaia.
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El7823 The Dsrk Side of High Prassure Stent Deployment
M.P.Savage, D.L. Fischman, J.S. Dougias, Jr., C.J. Pepine, J.A. Werner,
S.R. Bailey, R. Rake, S. Goldberg for the SAVED Investigators. Jefferson
Medical College, Philadelphia, PA, USA
High pressure dilatations have been shown to enhance the expanded ge-
ometry of coronaty stents and thus lessen the risk of thrombotic closure.
However, the longer term effects of high pressure inflations on vascular
healing and neointimal proliferation remain unknown. The SAphenous VEin
De Novo (SAVED) Trial was conducted from January 1993 to June 1995, a
period during which the use of high pressure stent deployment evolved into
routine clinical practice; use of high pressure inflations (?16 atm) significantly
increased during the later stages of the trial (p e 0.001). In this substudy
analysis, we compared the 6 month angiographic results of stentad vein
graft lesions treatad with high (?16 atm) and lower (S 15 atm) pressure de-
ployment. Of 105 patients treatad with Palmaz-Schatz stents, angiographic
follow-up at 6 months was performed in 90% of eligible patients. Quantitative
coronary angiographic reaults (mean valuee in mm) were as follows:
Pressure Lesion(n) Ref Dia Length Pre-mld Post-mid 6 mo mld
Low 88 3.23 10.0 0.85 2,86 1,91
High 31 3.03 6.8 0.80 2.82 1.26
P ns ns na ns <0.01
Therefore, atented lesions treated with high pressure inflations demon-
strated significantly smaller minimal Iuminal diameter at6monthsthan lesions
treated with lower pressure inflations. The suboptimal 8 month outeeme with
high pressure inflations was due to the significantly greater late loss in this
group (1.47 versus 0.91 mm, p < 0.01). These results strongly suggeet that
the deployment of stents with 2-16atm distending pressure has a deleterious
effect on late lumen loss and 6 month angiographic outcome in vein grafts,
presumably due to increased neointimal proliferation within the stent.
‘p <0.05 (s 16 vs SuboptimslvaOptimsl),*P <0.05 (s 16 vs SubOptimsO,‘P <0.05
(S 16va >16), *p <0.05 (s 16 and Optimalva Suboptimal)
In conclusion, this retrospective analysis suggests that the restenosis
rate after stenting is not affected by high-pressure stent expansion. A higher
